Sign Up Today and Learn More About SpringWorks Therapeutics Stock
Invest in or calculate the value of your shares in SpringWorks Therapeutics or other pre-IPO companies through EquityZen's platform.
SpringWorks Therapeutics Stock
SpringWorks is a medicines company.
About SpringWorks Therapeutics Stock
Founded
2017
Headquarters
Baltimore, MD, US
Total Funding
103M
Industries
Science and Engineering, Health Care, Biotechnology
They are a different type of therapeutic development company purpose-built for the 21st century. SpringWorks Therapeutics is on a mission to connect scientists, biopharmaceutical partners, patient groups, funders and philanthropists to deliver promising, transformative science to underserved patients. Their name symbolizes their mission-driven approach to therapeutic development—they’re springing into action to deliver treatments to people who are in urgent need.
SpringWorks Therapeutics Press Mentions
Stay in the know about the latest news on SpringWorks Therapeutics
SpringWorks Therapeutics to Present at Cowen and Company's 38
Business Wire (press release) • Mar 05, 2018
These Maryland companies received the most venture capital in 2017
Baltimore Business Journal • Feb 02, 2018
Pfizer spin-off SpringWorks embraces shelved therapies
MedCity News • Sep 29, 2017
Pfizer Spin Off Lands $103M to Develop New Drugs for Undeserved Patient Populations
HIT Consultant • Sep 27, 2017
SpringWorks Therapeutics Management
Leadership team at SpringWorks Therapeutics
President and Founder
Lara S. Sullivan
Executive Chairman
Daniel S. Lynch
Join now and verify your accreditation status to gain access to:
- SpringWorks Therapeutics current valuation
- SpringWorks Therapeutics stock price
- Available deals in SpringWorks Therapeutics and all other companies
- Deal offering documents
- EquityZen's proprietary data and insights, including
- Cap tables, which include funding history by Share Class and Liquidity Preferences
- Company Highlights
- Business Model
- Risk Factors
How to invest in SpringWorks Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like SpringWorks Therapeutics through EquityZen funds. These investments are made available by existing SpringWorks Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell SpringWorks Therapeutics stock?
Shareholders can sell their SpringWorks Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 320K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
